Arianna Zappaterra, Ivan Civettini, Anna Maria Cafro, Laura Pezzetti, Silvia Pierini, Michela Anghilieri, Laura Bellio, Paola Bertazzoni, Giovanni Grillo, Periana Minga, Maria L Pioltelli, Emanuele Ravano, Marianna Sassone, Clara V Viganò, Elisabetta B Volpato, Carlo Gambacorti-Passerini, Silvano Rossini, Roberto Cairoli, Roberto Crocchiolo
BACKGROUND: Induction with daratumumab-based regimens followed by autologous stem cell transplantation is the current standard for newly diagnosed multiple myeloma (NDMM) patients eligible for intensive chemotherapy. However, concerns emerged regarding potential negative effects following daratumumab-based treatment on CD34+ mobilization. We here compared CD34+ mobilization and clonogenic potential between daratumumab and non-daratumumab based therapy without upfront plerixafor administration among patients affected by NDMM...
January 24, 2024: Blood Transfusion